The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).
 
Lilit Karapetyan
No Relationships to Disclose
 
Arivarasan Karunamurthy
No Relationships to Disclose
 
Anthony Cillo
No Relationships to Disclose
 
Shuachao Wang
No Relationships to Disclose
 
Ryan Campbell Massa
No Relationships to Disclose
 
Anjali Rohatgi
No Relationships to Disclose
 
Christopher Deitrick
No Relationships to Disclose
 
Yana G. Najjar
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; InterVenn Biosciences; Mallinckrodt/Therakos; Merck; Pfizer
Speakers' Bureau - Immunocore; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer/EMD Serono (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Istari
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Cindy Sander
No Relationships to Disclose
 
Amy Rose
No Relationships to Disclose
 
Elizabeth Rush
No Relationships to Disclose
 
Marion Joy
No Relationships to Disclose
 
Sheryl Kunning
No Relationships to Disclose
 
Riyue Bao
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Tullia C. Bruno
Consulting or Advisory Role - Walking Fish Therapeutics
 
Dario Vignali
Leadership - F-Star; Tizona Therapeutics, Inc.; Werewolf Therapeutics
Stock and Other Ownership Interests - Oncorus; Tizona Therapeutics, Inc.; TTMS; Werewolf Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; G1 Therapeutics; Innovent Biologics; Kronos Bio
Research Funding - Astellas Pharma; Bristol-Myers Squibb; TTMS
Patents, Royalties, Other Intellectual Property - Astellas Pharma; Tizona Therapeutics, Inc.; TTMS
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Fstar Therapeutics; Tizona Therapeutics, Inc.; Werewolf Therapeutics
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Bristol Myers Squibb; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; CytomX Therapeutics; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lytix Biopharma; Magnolia Innovation; Merck; Natera; Novartis; OncoCyte; OncoSec; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda; Valar Labs
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron